Adam Brufsky

Prognostic value of visually and computationally assessed tumor-infiltrating lymphocytes in early-stage triple-negati...

Journal of the National Cancer Institute · 1 januari 2026

Sacituzumab Govitecan in Untreated, Gevorderd Triple-Negative Breast Cancer.

The New England journal of medicine · 13 november 2025

Eerstelijns Camizestrant for Emerging ESR1-Mutated Gevorderd Breast Cancer.

The New England journal of medicine · 7 augustus 2025

Sacituzumab govitecan bij gemetastaseerd TNBC: ASCENT definitieve resultaten

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 20 mei 2024

Enobosarm (selectieve androgeenreceptormodulator) bij AR-positief mammacarcinoom

The Lancet. Oncology · 2024-03

Sacituzumab govitecan bij gemetastaseerd TNBC: ASCENT fase III

The New England journal of medicine · 22 april 2021

Neratinib plus capecitabine versus lapatinib plus capecitabine bij HER2-positief mammacarcinoom: NALA fase III

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 20 september 2020

Fulvestrant plus everolimus of placebo bij HR-positief gevorderd mammacarcinoom: BOLERO-6 fase II

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 1 juni 2018

Publicaties op Oncologisch.com